Entero Therapeutics, Inc. (NASDAQ:GRDX) Short Interest Update

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 65,966 shares, a decrease of 44.6% from the August 15th total of 118,986 shares. Based on an average daily trading volume, of 144,450 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.9% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded shares of Entero Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 29th.

Entero Therapeutics Trading Up 2.7%

Shares of NASDAQ:GRDX traded up $0.08 during trading on Thursday, reaching $3.02. The stock had a trading volume of 80,519 shares, compared to its average volume of 118,045. The company has a market capitalization of $21.53 million, a P/E ratio of -1.59 and a beta of 1.87. The firm’s 50-day simple moving average is $3.42 and its 200 day simple moving average is $3.47. Entero Therapeutics has a one year low of $1.87 and a one year high of $6.93.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.